Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Intangibles (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Intangibles for 6 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles fell 33.87% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, down 33.87%, and an annual FY2024 reading of $3.1 million, up 117.33% over the prior year.
  • Intangibles was $2.0 million for Q3 2025 at Sunshine Biopharma, down from $3.1 million in the prior quarter.
  • Across five years, Intangibles topped out at $3.1 million in Q4 2024 and bottomed at $776856.0 in Q4 2022.
  • Average Intangibles over 4 years is $1.8 million, with a median of $1.4 million recorded in 2023.
  • The sharpest move saw Intangibles skyrocketed 149.84% in 2024, then crashed 33.87% in 2025.
  • Year by year, Intangibles stood at $776856.0 in 2022, then surged by 85.91% to $1.4 million in 2023, then skyrocketed by 117.33% to $3.1 million in 2024, then crashed by 35.98% to $2.0 million in 2025.
  • Business Quant data shows Intangibles for SBFM at $2.0 million in Q3 2025, $3.1 million in Q4 2024, and $3.0 million in Q3 2024.